Firefly Neuroscience

Executive Summary

Firefly Neuroscience is an Israeli med-tech company commercializing the FDA-cleared Evoke™ platform, a cloud-based neurodiagnostic system that combines quantitative EEG, event-related potentials, and AI-driven analytics to generate objective, age-matched brain-function reports. The platform aids clinicians in diagnosing and monitoring neurological and psychiatric disorders such as ADHD, dementia, and depression. By providing quantitative, reproducible brain data, Evoke addresses the critical need for objective biomarkers in mental health, potentially reducing diagnostic delays and improving treatment outcomes. The company has secured FDA clearance and is focused on clinical adoption, reimbursement strategies, and expanding its evidence base through peer-reviewed studies. With a lean commercial team and a scalable software-as-a-service model, Firefly is positioned to disrupt the traditionally subjective field of neuropsychiatric assessment.

Upcoming Catalysts (preview)

• Q2 2027Reimbursement Milestone: New CPT Codes or Coverage Decision40% success
• Q1 2027Strategic Partnership with Pharmaceutical or Diagnostics Company35% success
• Q4 2026Expansion to European Market via CE Mark Approval60% success